Loading clinical trials...

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

A Dose-ranging Study to Examine the Pharmacokinetics, Safety, Tolerability and Efficacy of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

NCT04976738•Cymra Life Sciences

View on ClinicalTrials.gov

Summary

This is a non-randomised, single arm, open-label study of medical cannabis, Cybis™ 10:25, in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25.

Detailed Description

This is a non-randomised, single arm, open-label study of Cybis™ 10:25 in participants with chronic back or neck pain in which participants receive escalating doses of Cybis™ 10:25. The purpose of the study is to demonstrate the safety and tolerability of Cybis™ 10:25 in participants with moderate to severe chronic back or neck pain that is unresponsive to over-the-counter non-opioid analgesics. Participants will undergo a screening visit, then seven clinic visits (Day 1, 2, 8, 15, 22, 29, and 35). Cybis™ 10:25 will be administered oromucosally at doses varying from 0.5 mL once daily to 1.5 mL twice daily. Total duration of dosing is 28 days.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Aged over 18 years and less than 75 years of age on the date of the Screening Visit;
•2. Have back and or neck pain of at least three months duration;
•3. Have an average back or neck pain score of between 5 and 9 on a 10-point visual analogue pain scale;
•4. Have failed to achieve self-reported satisfactory pain relief using over-the-counter paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs);
•5. Are willing to cease all current pain medications 14 days prior to commencing Cybis™ 10:25, and for the duration of the study (except as allowed under rescue medication); Note: Pain medication may include opioids (including but not limited to paracetamol+codeine combinations, codeine, tramadol, tapentadol, buprenorphine), NSAIDs and other co-analgesic medications (such as anti-epileptics, antidepressants, clonidine) and/or any other pain medications.
•6. Agree to cease any dietary or herbal supplements (e.g. St John's Wort) fourteen days prior to commencing Cybis™ 10:25, and for the duration of the study;
•7. Are willing to cease driving a car or operating heavy machinery from the day of first dosing to seven days after administration of the last dose of Cybis™ 10:25;
•8. Agree to use contraception throughout the study, and for one month after the last dose of Cybis™ 10:25 is administered (if reproductive age female) or three months after the last dose of Cybis™ 10:25 is administered (if male); Note: women of childbearing potential must have a negative serum or urine pregnancy test prior to entry into the study. For women, adequate contraception is a double barrier method for the duration of the study and for 30 days post the last study dose. For men, barrier contraception is required for the duration of the study and for 3 months after the last study dose.
•9. Agree to adhere to the study protocol; and
•10. Are willing and able to provide written informed consent.

Exclusion Criteria

•1. Are pregnant or breastfeeding;
•2. Currently using marijuana or other medicinal cannabis products; Use of medical cannabis products \> 6 months prior to Screening is acceptable;
•3. History of cannabis use disorder (score of 8 or higher on The Cannabis Use Disorder Identification Test - Revised (CUDIT-R);
•4. Current or previous allergies or allergic responses to any of the components of the study treatment (e.g., THC, CBD, MCT);
•5. Current or previous allergies or allergic responses to any of the components of the rescue medication (e.g. paracetamol, ibuprofen, aspirin, other NSAIDs);
•6. Significant cardiac disease (e.g. poorly controlled hypertension, symptomatic ischaemic heart disease, symptomatic heart failure);
•7. Chronic liver disease with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 times the upper level or normal limits;
•8. Chronic renal impairment with eGFR \<30mL/min;
•9. Taking sildenafil or other PDE5 inhibitors;
•10. Being treated with known inducers/inhibitors of CYP3A4, in particular clarithromycin, rifampicin, azole antifungals, antiretroviral agents, anticonvulsants (phenytoin, carbamazepine), SSRI within 30 days of study commencement; Use of such enzyme-altering agents is prohibited throughout the study.
+13 more criteria

Locations (2)

ACRN - Australian Clinical Research Network

Maroubra, New South Wales, Australia

Holdsworth House Medical Practice

Sydney, New South Wales, Australia

Key Dates

Start Date

September 20, 2021

Primary Completion Date

June 15, 2022

Completion Date

June 21, 2022

Last Updated

July 7, 2022

Enrollment

ACTUAL participants

Conditions

Chronic PainNeck PainBack PainPainPain, ChronicPain, BackPain, NeckCBDTHC

Interventions

Cybis™ 10:25 THC:CBD oil

DRUG

Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes

NCT06661850

Discogenic Low Back Pain

View study

RECRUITINGNA

Study of the Contribution of Osteopathic Treatment to Classic Medical Management in Patients With Chronic Low Back Pain

NCT03836248

Chronic Low Back Pain

View study

RECRUITINGNA

Optimization of NIBS for Treatment of Addiction

NCT04379115

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 7, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain

Inclusion Criteria

Exclusion Criteria

Examination of Nociscan Impact on Discogenic Low Back Pain Surgical Outcomes

Study of the Contribution of Osteopathic Treatment to Classic Medical Management in Patients With Chronic Low Back Pain

Optimization of NIBS for Treatment of Addiction

Effect of High-power Laser Acupuncture on Fatigue and Proprioception in Low Back Pain

Time to BBVNA Relief

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)